See analyst estimates and all valuation multiples for Chemicals
Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
---|---|---|---|
$243B | 7.3x | 18.4x | |
$102B | 4.4x | 22.7x | |
$85.0B | 5.3x | 22.6x | |
$81.0B | 6.7x | 16.0x | |
$71.7B | 1.0x | 8.2x | |
$48.7B | 2.8x | 7.5x | |
$47.1B | 1.3x | 9.2x | |
$43.6B | 8.6x | 2626.8x | |
$43.4B | 1.6x | 9.5x | |
$42.9B | 3.0x | 15.4x | |
$39.9B | 1.5x | 6.8x | |
$37.1B | 2.9x | 11.3x | |
$34.8B | 1.1x | 9.9x | |
$33.0B | 0.8x | 8.4x | |
$32.6B | 6.9x | 18.7x | |
$31.1B | 2.0x | 10.8x | |
$31.0B | 0.9x | 6.6x | |
$29.5B | 0.9x | 8.8x | |
$28.0B | 1.9x | 10.6x | |
$27.6B | 7.0x | 38.9x | |
$24.3B | 4.2x | 10.6x | |
$23.3B | 2.0x | 11.6x | |
$23.1B | 2.1x | 10.9x | |
$22.1B | 3.5x | 10.0x | |
$20.2B | 2.3x | 10.0x | |
$19.2B | 0.5x | 2.4x | |
$18.6B | 4.6x | 15.2x | |
$18.4B | 2.5x | 15.4x | |
$17.2B | 1.7x | 8.3x | |
$16.7B | 1.4x | 9.8x | |
$16.6B | 6.7x | 22.3x | |
$16.1B | 1.0x | 14.6x | |
$15.8B | 2.7x | 12.9x | |
$15.8B | 2.4x | 6.1x | |
$15.3B | n/a | n/a | |
$14.6B | 3.0x | 11.0x | |
$14.4B | 1.2x | 8.6x | |
$13.5B | 2.7x | 13.1x | |
$13.4B | 2.0x | 8.0x | |
$12.7B | 1.4x | 7.8x | |
$12.6B | 0.7x | 5.4x | |
$12.4B | 0.8x | 5.1x | |
$12.2B | 3.8x | 10.1x | |
$12.0B | 5.3x | 11.6x | |
$11.4B | 0.8x | 10.6x | |
$11.1B | 1.5x | 7.2x | |
$9.5B | 1.8x | 8.4x | |
$8.8B | 0.5x | 5.5x | |
$8.6B | 3.1x | n/a | |
$8.5B | 2.0x | 9.4x | |
$8.4B | 0.6x | 2.9x | |
$8.2B | 0.8x | 5.0x | |
$7.9B | 1.4x | 11.9x | |
$7.2B | 2.9x | 13.4x | |
$6.8B | 3.0x | -101.6x | |
$6.6B | 2.8x | 8.3x | |
$6.6B | 0.7x | 6.2x | |
$6.4B | 0.8x | 5.6x | |
$6.2B | 1.1x | 7.8x | |
$6.1B | 6.5x | 24.3x | |
$6.1B | 0.6x | 7.6x | |
$6.0B | 1.6x | 7.1x | |
$5.9B | 3.0x | 11.9x | |
$5.8B | 0.9x | 7.4x | |
$5.6B | 6.9x | 24.0x | |
$5.6B | 1.4x | 9.1x | |
$5.6B | 1.1x | 5.1x | |
$5.5B | 1.1x | 9.5x | |
$5.4B | 3.4x | 19.4x | |
$5.4B | 5.3x | 20.2x | |
$5.3B | 1.4x | 6.5x | |
$5.3B | 1.5x | 8.6x | |
$5.2B | 1.0x | 6.2x | |
$5.2B | 0.7x | 7.9x | |
$4.9B | 1.5x | 9.0x | |
$4.7B | n/a | n/a | |
$4.6B | 0.7x | 5.9x | |
$4.2B | 16.5x | 84.6x | |
$4.0B | 0.4x | 11.6x | |
$4.0B | 0.7x | 12.3x | |
$3.9B | 7.0x | 14.2x | |
$3.9B | 1.6x | 12.1x | |
$3.8B | 3.7x | 21.8x | |
$3.8B | 1.8x | 8.3x | |
$3.8B | 2.0x | 9.3x | |
$3.8B | 1.1x | 5.9x | |
$3.7B | 1.2x | 8.0x | |
$3.7B | 0.9x | 15.4x | |
$3.6B | n/a | n/a | |
$3.5B | 1.7x | 9.2x | |
$3.4B | 2.6x | 8.9x | |
$3.2B | 1.7x | 10.5x | |
$2.9B | 4.8x | 26.3x | |
$2.9B | 11.0x | 34.8x | |
$2.9B | 0.4x | 4.6x | |
$2.9B | n/a | n/a | |
$2.8B | 0.8x | -536.9x | |
$2.7B | n/a | n/a | |
$2.5B | n/a | n/a | |
$2.5B | 0.7x | 12.4x | |
$2.4B | 0.8x | 7.2x | |
$2.3B | 0.2x | 7.4x | |
$2.2B | 2.9x | 11.6x | |
$2.2B | 0.8x | 6.7x | |
$2.1B | 1.6x | 3.2x | |
$2.1B | 2.1x | 11.1x | |
$1.9B | 1.1x | 9.1x | |
$1.9B | 2.4x | 7.6x | |
$1.7B | 0.8x | 8.3x | |
$1.7B | 0.4x | 2.4x | |
$1.6B | 2.5x | 12.5x | |
$1.6B | 0.8x | 6.2x | |
$1.6B | 0.8x | 5.5x | |
$1.5B | 1.5x | 8.5x | |
$1.5B | 1.5x | 6.8x | |
$1.4B | 1.2x | 9.3x | |
$1.4B | 2.1x | 9.8x | |
$1.4B | 2.7x | n/a | |
$1.4B | n/a | n/a | |
$1.3B | 0.7x | 9.3x | |
$1.2B | 0.5x | 34.2x | |
$1.1B | 1.0x | 2.5x | |
$1.1B | 1.3x | 4.9x | |
$1.1B | 2.8x | 48.9x | |
$1.0B | 1.0x | 10.3x | |
$995M | 0.5x | 22.3x | |
$963M | 1.7x | 7.2x | |
$923M | 0.6x | 6.5x | |
$912M | 0.4x | n/a | |
$831M | 51.9x | n/a | |
$784M | n/a | n/a | |
$761M | n/a | n/a | |
$586M | 0.5x | 3.8x | |
$566M | 1.0x | 7.7x | |
$561M | 10.6x | 35.6x | |
$547M | 1.2x | 6.0x | |
$543M | n/a | n/a | |
$537M | n/a | n/a | |
$530M | 5.2x | -34.3x | |
$513M | 0.4x | 6.2x | |
$499M | 1.8x | -56.4x | |
$484M | 0.9x | 5.7x | |
$471M | 0.7x | 6.3x | |
$408M | 1.1x | 7.4x | |
$400M | 0.7x | 5.4x | |
$398M | 0.7x | 2.4x | |
$370M | 1.5x | 10.9x | |
$360M | n/a | n/a | |
$348M | 0.6x | 8.6x | |
$340M | n/a | n/a | |
$334M | 1.5x | 8.5x | |
$323M | 1.3x | 6.5x | |
$314M | 0.2x | 3.1x | |
$294M | n/a | n/a | |
$284M | 7.3x | -7.0x | |
$256M | n/a | n/a | |
$246M | n/a | n/a | |
$212M | n/a | n/a | |
$211M | 1.4x | n/a | |
$204M | n/a | n/a | |
$196M | 0.2x | 85.8x | |
$186M | 7.3x | -6.9x | |
$177M | 0.4x | 4.5x | |
$166M | n/a | n/a | |
$165M | 180.3x | -193.0x | |
$158M | 0.4x | 3.2x | |
$156M | n/a | n/a | |
$144M | 1.2x | 6.7x | |
$141M | 0.6x | 3.9x | |
$132M | 33.7x | -4.2x | |
$125M | n/a | n/a | |
$101M | 5.1x | 15.5x | |
$96.3M | 6.0x | -4.4x | |
$95.1M | n/a | n/a | |
$84.7M | 309.1x | -13.6x | |
$81.9M | n/a | n/a | |
$78.7M | 0.6x | 8.5x | |
$75.7M | n/a | n/a | |
$74.8M | n/a | n/a | |
$72.9M | 0.9x | n/a | |
$66.9M | 10.0x | -6.3x | |
$63.9M | 1.1x | 55.1x | |
$61.6M | n/a | n/a | |
$61.1M | 0.7x | 4.2x | |
$50.9M | 0.6x | 4.9x | |
$46.1M | 0.7x | 13.4x | |
$43.9M | 0.5x | 12.6x | |
$42.9M | n/a | n/a | |
$41.9M | 11.7x | -6.4x | |
$34.3M | n/a | n/a | |
$32.3M | 1.5x | 27.9x | |
$29.0M | 1.8x | 15.1x | |
$27.7M | n/a | n/a | |
$27.5M | n/a | n/a | |
$25.5M | 2.0x | 71.8x | |
$21.9M | n/a | n/a | |
$21.6M | 2.0x | -10.1x | |
$21.3M | n/a | n/a | |
$21.0M | n/a | n/a | |
$18.7M | n/a | n/a | |
$17.7M | n/a | n/a | |
$17.0M | n/a | n/a | |
$16.5M | n/a | n/a | |
$12.3M | n/a | n/a | |
$11.6M | 1.1x | -4.4x | |
$9.2M | 2.0x | -5.7x | |
$7.2M | n/a | n/a | |
$5.7M | n/a | n/a | |
$5.7M | 111.0x | -7.5x | |
$5.6M | n/a | n/a | |
$5.3M | n/a | n/a | |
$5.0M | 2.7x | -9.4x | |
$4.5M | n/a | n/a | |
$3.3M | n/a | n/a | |
$3.1M | n/a | n/a | |
$2.4M | 18.4x | -0.6x | |
$2.2M | n/a | n/a | |
$1.9M | n/a | n/a | |
$1.7M | n/a | n/a | |
$1.7M | n/a | n/a | |
$1.6M | 4.5x | -0.1x | |
$1.1M | n/a | n/a | |
$1.1M | n/a | n/a | |
$1.0M | n/a | n/a | |
-$5.0M | n/a | n/a | |
-$60.3M | -0.0x | -1.7x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Chemicals